Intervencionista
Un ensayo clínico en el que se usa un nuevo medicamento o dispositivo para medir un resultado específico.
FSGS Clinical Research Study
A study to test BI 764198 in people with a type of kidney disease called focal segmental glomerulosclerosis (FSGS)
This study is being done to see if the study drug, called BI 764198, may help people with FSGS. The study drug or a placebo will be taken as a capsule by mouth one (1) time every day for about 12 weeks.
Médico del ensayo/Coordinador del estudio
Moravia Vasallo
Correo electrónico Número de teléfono 915-306-4669Nombre del sitio
MedResearch, Inc.
1201 East Schuster Avenue, BLDG 1 A
Intervencionista
Un ensayo clínico en el que se usa un nuevo medicamento o dispositivo para medir un resultado específico.
FSGS Clinical Research Study
A study to test BI 764198 in people with a type of kidney disease called focal segmental glomerulosclerosis (FSGS)
This study is being done to see if the study drug, called BI 764198, may help people with FSGS. The study drug or a placebo will be taken as a capsule by mouth one (1) time every day for about 12 weeks.
Criterios de elegibilidad
Población de pacientes
Primary FSGS or documented Transient Receptor Potential Cation subfamily C Member 6 (TRPC6) gene mutation causing FSGS.
Edad
18 — 26+
¿Pueden los pacientes con trasplante de riñón calificar para este ensayo?
No
¿Los pacientes que se encuentran actualmente en diálisis pueden calificar para este ensayo?
No
TFGe
UPCR
¿Qué tratamientos pueden haber tomado los pacientes para calificar para este ensayo?
Inhibidores ACE/ARB, Prednisona (Esteroides), Ninguno
¿Qué tipo de pacientes de las categorías siguientes pueden participar?
Resistente al tratamiento, Dependiente de esteroides
Sobre el medicamento o la intervención
Qué implica para el paciente
Patients will be asked to allow researchers to access medical history. This trial consists of a Screening Period, a Study Drug Period, an End of Treatment Visit, and a Follow-Up Period. There are about 10 visits and 1 phone call visit to participate in the trial. The study staff or study doctor may complete the following procedures during each study visit: ECG, 24 hour urine collection (instructions/collection diary distribution), collect lab samples for safety testing (blood or urine), collect biomarker samples (blood or urine) which is optional, Pharmacokinetic (PK) samples (urine), and eye exams.
Nombre del patrocinador
Boehringer Ingelheim Pharmaceuticals, Inc.
Fecha estimada de finalización
October 2024
Sobre el estudio
Nombre del fármaco del estudio
BI 764198
Objetivo del estudio
This study is being done to:
• Test different doses of the study drug, BI 764198, for safety, effectiveness, and side effects, when compared to taking a placebo, in subjects with focal segmental glomerulosclerosis (FSGS).
In this study, you will either get the active study drug, BI 764198, or a placebo.
• Test how the study drug is used by the body, and how fast or slow the study drug moves through or out of the body.
Sobre el medicamento o la intervención
BI 764198 is taken orally as a capsule once daily.